Q2 2020 13F Holders as of 6/30/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
157M
-
Number of holders
-
167
-
Total 13F shares, excl. options
-
81.1M
-
Shares change
-
+18.4M
-
Total reported value, excl. options
-
$1.58B
-
Value change
-
+$377M
-
Put/Call ratio
-
0.57
-
Number of buys
-
109
-
Number of sells
-
-54
-
Price
-
$19.48
Significant Holders of TG THERAPEUTICS, INC. - Common Stock (TGTX) as of Q2 2020
206 filings reported holding TGTX - TG THERAPEUTICS, INC. - Common Stock as of Q2 2020.
TG THERAPEUTICS, INC. - Common Stock (TGTX) has 167 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 81.1M shares
of 157M outstanding shares and own 51.54% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (12.8M shares), FMR LLC (12.7M shares), BlackRock Inc. (7.08M shares), VANGUARD GROUP INC (5.46M shares), STATE STREET CORP (5.03M shares), GREAT POINT PARTNERS LLC (3.32M shares), Eversept Partners, LP (2.5M shares), ALKEON CAPITAL MANAGEMENT LLC (2.27M shares), Artal Group S.A. (1.75M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.5M shares).
This table shows the top 167 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.